Genmab — Januar 2024
-
Research analysts at William Blair lifted their FY2023 earnings per share (EPS) estimates for Genmab A/S in a research report issued on Tuesday, January 23rd. William Blair analyst M. Phipps now forecasts that the company will earn $1.32 per share for the year, up from their previous forecast of $1.30. The consensus estimate for Genmab A/S's current full-year earnings is $1.19 per share. https://www.marketbeat.com/instant-alerts/nasdaq-gmab-analyst-earnings-estimates-2024-01-25/
-
Jeg er ret sikker på at fælles for de to grupper Legolas nævner er at deltagerne alle er glade for og stolte over at være interessenter i en virksomhed der har gjort så meget godt for patienterne. For ikke så mange år siden var MM en sikker dødsdom. Det er det heldigvis ikke mere og tak for det Genmab og professor Plesner og alle andre der har bidraget til udviklingen af Dara.
-
Video...Genmab er i vælten, især efter afvisningen af voldgiftsagen. Men hvad er udsigterne for 2024? Zealand Pharma-aktien bliver ved med at stige - hvad driver stigningen, og er det holdbart? Novo Nordisk kommer med regnskab 31. januar - det har mange investorer store forventninger til. Et andet spændende regnskab er Bavarian Nordic. Hvad skal pengene i kassen bruges til? Det har Helge Larsen et bud på. Til sidst er der nyt fra Lundbeck og ALK-Abelló. https://www.proinvestor.com/boards/118263
-
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind